# Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

> **NCT00924170** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Adult T-Cell Leukemia (ATL)

## Interventions

- **DRUG:** LMB-2
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00924170
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-31
- **Primary completion:** 2016-01-02
- **Final completion:** 2021-05-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00924170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00924170, "Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00924170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*